Media coverage
44Media coverage
Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet Plus Company Updates (PCU) Country United States Date 6/26/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet Global English (Middle East and North Africa Financial Network) Country Jordan Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People ... Media name/outlet ADVFN Deutschland Country Germany Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet Spoke.com Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet TickerTech.com Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet KSWO Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet KNDO KNDU Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet KHQ Right Now Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet NBC12 Online Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet KSLA Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet Venture Beat Profiles Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet WTOC TV Country Georgia Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet Kuam News 8 Country Guam Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet KAUZ Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet 14 WFIE Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet WMBF Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet Kait 8 Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet KLTV 7 Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet WLBT Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet News 9 Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet FOX 14 TV Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet WSFA Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet Live 5 WCSC Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet WBOC TV 16 Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet WFMJ 21 - TV Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet WTVM Country Georgia Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet KFMB-TV Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet 19 Action News Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet KOTV Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet WDAM-TV Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet WTOL-TV Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet KTRE Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet KWES NewsWest 9 Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet KTVN Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet KOAM TV Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet KFVS12 Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet Channel 8 Eyewitness News Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet Fox 19 Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet Wave 3 Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet WMCTV.com Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet WECT TV-6 Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet WLOX Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet Hawaii News Now Country United States Date 6/24/18 Persons Ralph A Defronzo Title Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications Media name/outlet WIS-TV Country United States Date 6/24/18 Persons Ralph A Defronzo